Developments and announcements of primary interest to NINDS-supported investigators,
referring physicians, scientists, and research directors.
Contents:
Program Announcements (Grant Applications) Sought on:
Patient Volunteers Needed for Studies on:
NINDS Seeks Applications for
Bioengineering Nanotechnology Research
The National Institute of Neurological Disorders and
Stroke (NINDS), the National Institute of Child Health and Human Development (NICHD), the
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National
Cancer Institute (NCI), the National Center for Research Resources (NCRR), the National
Eye Institute (NEI), the National Heart, Lung, and Blood Institute (NHLBI), the National
Human Genome Research Institute (NHGRI), the National Institute on Aging (NIA), the
National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of
Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute on
Deafness and Other Communication Disorders (NIDCD), the National Institute of Dental and
Craniofacial Research (NIDCR), the National Institute on Drug Abuse (NIDA), the National
Institute of Environmental Health Sciences (NIEHS), the National Institute of General
Medical Sciences (NIGMS), the National Institute of Mental Health (NIMH), the National
Institute on Alcohol Abuse and Alcoholism (NIAAA), and the National Library of Medicine
(NLM) invite applications for small business innovation research (SBIR) projects on
nanotechnologies useful to biomedicine.
Nanotechnology is the creation of functional materials,
devices, and systems through control of matter at the scale of 1 to 100 nanometers, and
the exploitation of novel properties and phenomena at the same scale. It is emerging as a
field critical for enabling essential breakthroughs that may have tremendous biomedical
potential.
Examples of potential research areas include studies on:
nanoplumbing components such as valves, microfluidic channels, and motors; logic circuits
based on quantum dots; development and improvement of techniques based on new principles
for probing biological properties and phenomena not well understood at the nanometer scale
and for characterizing nanoscale materials; development of fluorescent probes at the
nanometer scale for monitoring biochemical processes on the surface and inside a cell in
health and disease; creation of "smart" nanostructured biocompatible materials;
development of nanofabricated barriers to prevent rejection of implantable materials;
development of nanoparticles and nanospheres that enable controlled release of therapeutic
agents, antibodies, genes, and vaccines into targeted cells; and development of sensor
technologies for detection and analysis of biologically relevant molecular and physical
targets in samples from blood, saliva, and other body fluids, or for use in the research
laboratory, clinical specimens, and the living body.
For more information, potential applicants should contact
Dr. William Heetderks, Repair and Plasticity Cluster, NINDS, Neuroscience Center, 6001
Executive Boulevard, Room 2207, Bethesda, MD 20892; telephone: (301) 496-1447; fax: (301)
402-1501; e-mail: heet@nih.gov.
<top>
Applications for Bioengineering
Research Partnerships Sought
The National Institute of Neurological Disorders and
Stroke (NINDS), the National Institute of Child Health and Human Development (NICHD), the
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National
Cancer Institute (NCI), the National Center for Research Resources (NCRR), the National
Eye Institute (NEI), the National Heart, Lung, and Blood Institute (NHLBI), the National
Human Genome Research Institute (NHGRI), the National Institute on Aging (NIA), the
National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of
Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute on
Deafness and Other Communication Disorders (NIDCD), the National Institute of Dental and
Craniofacial Research (NIDCR), the National Institute on Drug Abuse (NIDA), the National
Institute of Environmental Health Sciences (NIEHS), the National Institute of General
Medical Sciences (NIGMS), the National Institute of Mental Health (NIMH), the National
Institute of Nursing Research (NINR), and the National Library of Medicine (NLM) invite
applications for grants to support bioengineering research partnerships (BRPs).
A BRP is a multidisciplinary research team that applies an
integrative, systems approach to develop knowledge and methods to prevent, detect,
diagnose, and treat disease, and to understand health and behavior. The partnership must
include bioengineering expertise in combination with basic and/or clinical investigators.
The field of bioengineering brings a perspective that is valuable for many of today’s
biological problems. It integrates principles from a diversity of fields—crossing the
boundaries of academia, science, medicine, and industry. The creativity of
interdisciplinary teams is resulting in new basic understanding, novel products, and
innovative technologies.
Examples of potential research areas include:
biomechanics; bioprocessing; bioelectrics, ion channels, and organ function; clinical
medicine, therapeutics, and drug delivery; combinatorial approaches to chemistry,
materials, genes, and therapeutics; functional genomics including microarray technology,
integrated systems, and analysis tools; imaging; nanotechnology; informatics and
computational methods; medical implants, biomembranes, sensors, and devices; complex
biological systems; organ culture systems and organogenesis; rehabilitation and
prostheses; cell and tissue engineering and biomaterials; tissue regeneration; integrative
physiology; and drug bioavailability.
For more information, potential applicants should contact
Dr. William Heetderks, Repair and Plasticity Cluster, NINDS, Neuroscience Center, 6001
Executive Boulevard, Room 2207, Bethesda, MD 20892; telephone: (301) 496-1447; fax: (301)
402-1501; e-mail: heet@nih.gov.
<top>
Research on Mechanisms in HIV
Dementia and Other CNS Diseases Encouraged
The National Institute of Neurological Disorders and
Stroke (NINDS), the National Institute of Mental Health (NIMH), the National Institute on
Drug Abuse (NIDA), and the National Institute on Aging (NIA) encourage grant applications
for research on common immunological and inflammatory mechanisms involved in HIV-1
associated dementia (HAD) and neurodegenerative and/or autoimmune diseases of the nervous
system such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and multiple
sclerosis (MS).
Immunologically mediated inflammatory processes are
well-known to produce cellular damage in HIV infection and autoimmune diseases such as MS.
In addition, there is growing—but still indirect—evidence that inflammatory
processes may be involved in the pathogenesis of age-related neurodegenerative disorders
such as AD. Although it has been demonstrated that neuronal damage associated with injury
or infection initiates apoptotic neuronal death, there is little data in human neurons to
define the mechanisms that might be involved. Research is needed to determine the events
producing neuronal cell death due to inflammation or infection that may be common to
diverse neurodegenerative or autoimmune diseases as well as those that may be unique to
HIV-1 infection.
Examples of potential research areas include studies on:
common pathways for activation of phagocytes/microglia and astroglia in HAD, autoimmune,
and neurodegenerative disorders; common glial responses to chemokines, cytokines, or other
inflammatory agents that have been identified as occurring in HAD, MS, or AD; the role of
chemokine receptors in the normal function of the brain; the role of glial cells in
providing neural protection both in infection and in immune-mediated injury;
identification of any common alterations in blood-brain barrier permeability found in HAD,
MS, or AD; the interaction of HIV-1 with other infectious agents; possible common
histopathological and histochemical changes in neurons, microglia, or astroglia that may
be found in neurodegenerative disorders, MS, or HAD using material from brain, animal
models, or tissue culture; the role of noninfectious environmental agents in modulating
activation of macrophages/microglia and astroglia during the progression of HAD, MS, or
AD; excitotoxicity or increased oxidative stress and their role in producing the apoptosis
observed in HAD and AD; and susceptibility genes that may be common to individuals
developing HAD, MS, or AD.
For more information, potential applicants should contact
Dr. A.P. Kerza-Kwiatecki, Neural Environment Cluster, NINDS, Neuroscience Center, 6001
Executive Boulevard, Room 2115, Bethesda, MD 20892; telephone: (301) 496-1431; fax: (301)
402-2060; e-mail: ak45w@nih.gov.
<top>
NINDS Seeks Applications for Research
on the Role of Microglia
The National Institute of Neurological Disorders and
Stroke (NINDS), the National Institute of Mental Health (NIMH), the National Center for
Research Resources (NCRR), the National Institute on Deafness and Other Communication
Disorders (NIDCD), and the National Institute on Drug Abuse (NIDA) invite applications for
research grants on the role of microglia in normal and abnormal immune responses in the
nervous system.
Microglia are a relatively under-recognized, widely
distributed cell population within brain parenchyma constituting about 1 to 2 percent of
all cells. They are well-known to neuropathologists because they harbor agents including
viruses such as HIV-1, treponema pallidum, fungi, and prions during sub-acute or chronic
central nervous system (CNS) infections. The ability of microglia to harbor HIV-1 has
excited new interest in these cells. As the major infected CNS cell, they play a key role
in the development of AIDS dementia possibly by production of toxic factors following
infection, or more directly by being unable to provide normal metabolic support for
neurons.
Examples of potential research include studies to: define
the relationship between the various types of microglia and macrophages and their cells of
origin within and without the nervous system; define phenotypic markers that characterize
microglia, distinguishing between microglial types and states of activation; investigate
mechanisms of activation of microglia and their relationships to activation of T cells;
delineate the contribution of microglia to the development of autoimmunity of the CNS via
antigen presentation or production of specific cytokines; advance studies of the
contributions of peripheral blood monocytes and macrophages to the presence of infected
resident microglia; investigate the ability of microglia to elaborate chemokines and
cytokines and to express receptors for chemokines and cytokines; investigate contributions
of perivascular microglia to the entry of T cells and blood macrophages into the CNS
across the blood-brain barrier; investigate the role of microglia in diseases such as
multiple sclerosis and HIV infections, including the etiology of AIDS dementia; and study
the potential of microglia to serve as therapeutic tools for delivery of drugs, enzymes,
trophic factors, or genes into the CNS.
For more information, potential applicants should contact
Dr. A. P. Kerza-Kwiatecki, Neural Environment Cluster, NINDS, Neuroscience Center, 6001
Executive Boulevard, Room 2115, Bethesda, MD 20892; telephone: (301) 496-1431; fax: (301)
402-2060; e-mail: ak45w@nih.gov.
<top>
NINDS Seeks Patients With Alzheimer's Disease
Investigators at the National Institute of Neurological
Disorders and Stroke (NINDS) are seeking patients with mild to moderate dementia for a
clinical trial of an experimental compound. This trial will be conducted at the National
Institutes of Health (NIH) Clinical Center in Bethesda, MD.
Eligible patients must be between the ages of 40 and 90,
otherwise healthy, and ambulatory, and they must be off all antidementia medications for 1
month. All treatment-related expenses will be paid by the NIH.
To refer eligible patients, physicians should send a
letter of referral and case summary to Dr. Thomas Chase, Chief, Experimental Therapeutics
Branch, NINDS, NIH, Building 10, Room 5C106, 10 Center Dr. MSC 1406, Bethesda, MD
20892-1406; fax: (301) 496-6609. Please call Kimberly Mosby with any questions at (301)
496-4604 or 1-800-362-3479.
<top>
Patients with Amnesia Sought for
Cognitive Neuroscience Studies
Scientists at the National Institute of Neurological
Disorders and Stroke (NINDS) studying neurobehavior are seeking patients with severe
isolated memory disorders due to anoxia, encephalitis, stroke, and other neurological or
behavioral disorders. Amnesia patients who are otherwise intellectually unimpaired are
especially needed.
Patients should be 18 to 65 years old and without immune,
respiratory, renal, hepatic, or gastrointestinal disease. Exceptions to this age range may
be made given extraordinary clinical presentation. Only patients residing in the United
States are eligible to participate in these studies.
The studies will be conducted at the National Institutes
of Health (NIH) Clinical Center in Bethesda, MD, and will include neuropsychological
testing, neuroimaging, and related evaluations. All study-related expenses will be paid by
the NIH.
For more information, physicians should contact Dr. Jordan
Grafman, Chief, Cognitive Neuroscience Section, Medical Neurology Branch, NINDS, NIH,
Building 10, Room 5C205, 10 Center Drive MSC 1440, Bethesda, MD 20892-1440; telephone:
(301) 496-0220; fax: (301) 480-2909; e-mail: grafmanj@ninds.nih.gov.
<top>
Patients with Cortical Basal
Ganglionic Degeneration Sought
Scientists at the National Institute of Neurological
Disorders and Stroke (NINDS) studying neurobehavior are seeking patients with cortical
basal ganglionic degeneration for cognitive neuroscience studies.
Eligible patients should be mild to moderately affected,
between the ages of 18 and 70, and have no other current significant disease. Those
enrolled in the study will undergo neuropsychological testing and brain imaging studies.
The studies will be conducted at the National Institutes of Health (NIH) Clinical Center
in Bethesda, MD. All study-related expenses will be paid by the NIH.
For more information, physicians should contact Dr. Jordan
Grafman, Chief, Cognitive Neuroscience Section, NINDS, Building 10, Room 5C205, 10 Center
Drive MSC 1440; Bethesda, MD 20892-1440; telephone: (301) 496-0220; fax: (301) 480-2909;
email: grafmanj@ninds.nih.gov.
<top>
Patients with Cortical Myoclonus
Needed
Scientists at the National Institute of Neurological
Disorders and Stroke (NINDS) are seeking patients with cortical myoclonus for
participation in a controlled therapeutic trial of transcranial magnetic brain
stimulation.
The trial will take place at the National Institutes of
Health (NIH) Clinical Center in Bethesda, MD. All trial-related expenses will be paid by
the NIH.
For more information, physicians should contact Stephanie
Vogel, Patient Care Coordinator, Human Motor Control Section, NINDS, NIH, Building 10,
Room 5N234, 10 Center Drive MSC 1430, Bethesda, MD 20892-1430; telephone: (301) 496-0600.
<top>
NINDS Seeks Adults with Focal
Frontal Lesions
Scientists at the National Institute of Neurological
Disorders and Stroke (NINDS) are seeking adults with frontal lobe lesions for a
longitudinal, prospective study of cognitive function.
To be eligible, patients must be between the ages of 16
and 70 and have a single focal lesion of the frontal lobes. Some of the possible causes of
such frontal lesions include: brain abscess, embolic stroke, intracerebral hemorrhage,
tumor, partial surgical resection, arteriovenous malformation, congenital hypoplasia,
aplasia porencephalic cysts, and penetrating head injuries. Patients will not be eligible
if they have ongoing, severe medical illness or other problems precluding successful
serial follow-up. A partial list of exclusion criteria includes history of: generalized or
multifocal brain injury, mental retardation, precocious puberty, severe closed head
trauma, elevated intracranial pressure, radiation therapy, intractable epilepsy, neonatal
intraventricular hemorrhage, congenital hydrocephalus from any cause, or the presence of a
ventriculoperitoneal shunt.
Studies to be done at the National Institutes of Health
(NIH) in Bethesda, MD, include magnetic resonance imaging, neurologic examination and
history, and cognitive testing. Records of all studies and evaluations will be made
available to the referring physician. All study-related expenses and certain travel
expenses will be paid by the NIH.
For more information, physicians should contact Dr. Jordan
Grafman, Chief, Cognitive Neuroscience Section, Medical Neurology Branch, NINDS, NIH,
Building 10, Room 5C205, 10 Center Drive MSC 1440, Bethesda, MD 20892-1440; telephone:
(301) 496-0220; fax: (301) 480-2909; e-mail: grafmanj@ninds.nih.gov.
<top>
Patients with Frontal Lobe Dementia
Needed
Investigators at the National Institute of Neurological
Disorders and Stroke (NINDS) conducting neurobehavioral studies are seeking patients with
progressive dementia diagnosed as Pick's disease, frontal lobe dementia, progressive
aphasia, or lobar atrophy of the frontal lobes. Patients with radiological evidence of
focal atrophy of the frontal lobes are particularly needed.
Eligible patients must not have concurrent immune,
respiratory, renal, hepatic, or gastrointestinal disease. Those enrolled in the study will
undergo neuropsychological testing and brain imaging studies. The studies will be
conducted at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD. All
study-related expenses will be paid by the NIH.
For more information, physicians should contact Dr. Jordan
Grafman, Chief, Cognitive Neuroscience Section, Medical Neurology Branch, NINDS, NIH,
Building 10, Room 5C205, 10 Center Drive MSC 1440, Bethesda, MD 20892-1440; telephone:
(301) 496-0220; fax: (301) 480-2909; e-mail: grafmanj@ninds.nih.gov.
<top>
Patients with HTLV-1-Associated Myelopathy
or Tropical Spastic Paraparesis Sought
Researchers at the National Institute of Neurological
Disorders and Stroke (NINDS) are seeking patients with HTLV-1-associated myelopathy or
tropical spastic paraparesis (HAM/TSP) for an experimental treatment trial. The study will
test an experimental drug's ability to ameliorate the immune dysregulation induced by
HTLV-1. Testing of this drug will be carried out in compliance with FDA guidelines.
Eligible patients must be at least 16 years of age, meet
diagnostic criteria for HAM/TSP, and be negative for HIV, HCV, and hepatitis B surface
antigen. The studies will be conducted at the National Institutes of Health (NIH) Clinical
Center in Bethesda, MD. All study-related expenses will be paid by the NIH.
For more information, physicians should send a referral
letter and a copy of the patient's recent medical records to Joan Eaton, RN, CRNP,
Neuroimmunology Branch, NINDS, NIH, Building 10, Room 5B16, 10 Center Drive MSC 1430,
Bethesda, MD 20892-1430; telephone: (301) 496-0064; fax: (301) 402-0373; email: eatonj@ninds.nih.gov.
<top>
NINDS Seeks Patients with Multiple Sclerosis
Researchers at the National Institute of Neurological
Disorders and Stroke (NINDS) are seeking patients with multiple sclerosis (MS) for an
experimental treatment trial. The study will test an experimental drug's ability to reduce
disease activity as seen on magnetic resonance imaging (MRI) scans. Testing of this drug
will be carried out in compliance with FDA guidelines.
Eligible patients must be 18 to 65 years old, have
relapsing/remitting or secondary progressive MS, and be taking Avonex or Betaseron for at
least a 6-month period and continuing to have exacerbations. The studies will be conducted
at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD. All
study-related expenses will be paid by the NIH.
For more information, physicians should send a referral
letter and a copy of the patient's recent medical records to Joan Eaton, RN, CRNP,
Neuroimmunology Branch, NINDS, NIH, Building 10, Room 5B16, 10 Center Drive MSC 1430,
Bethesda, MD 20892-1430; telephone: (301) 496-0064; fax: (301) 402-0373; email: eatonj@ninds.nih.gov.
<top>
NINDS Accepts Organ Donations for Multiple
Sclerosis Research
In the Neuroimmunology Branch of the National Institute of
Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH)
multiple sclerosis (MS) research has been ongoing for the past 30 years. Studying the
pathology of brain tissue is a vital part of this research, which may enable us to
determine the cause of MS.
Many people have expressed interest in organ donation for
the purpose of MS research. Gifts of brain and spinal cord from those who have a diagnosis
of MS are invaluable to the further understanding of this disease.
For more information, physicians should contact Joan
Eaton, RN, CRNP, or Jennifer McCartin, RN, Neuroimmunology Branch, NINDS, NIH, Building
10, Room 5B16, 10 Center Drive MSC 1430, Bethesda, MD 20892-1430; telephone: (301)
496-0064; fax: (301) 402-0373; email: eatonj@ninds.nih.gov.
The Neuroimmunology Branch is grateful for your
contribution to continuing research in multiple sclerosis.
<top>
Patients with
Neuroacanthocytosis Sought for Cognitive Neuroscience Studies
Scientists at the National Institute of Neurological
Disorders and Stroke (NINDS) studying neurobehavior are seeking patients with
neuroacanthocytosis (X-linked [McLeod syndrome], non-X-linked, and sporadic patients are
eligible) to examine the role of the basal ganglia in this disease.
Eligible patients must be referred by a physician, should
be ambulatory, and must be able to travel to Bethesda, MD, for testing. They should
present with acanthocytosis either in the setting of the McLeod phenotype or in
association with neurological signs such as neuromyopathy or cerebral involvement.
Patients with abetalipoproteinemia (Bassen-Kornzweig) or neuroaxonal dystrophy
(Hallervorden-Spatz) are not eligible.
The studies will be conducted at the National Institutes
of Health (NIH) Clinical Center in Bethesda, MD, and will include experimental
neuropsychological testing, functional and structural neuroimaging, and a neurological
evaluation. All study-related expenses will be paid by the NIH.
For more information, physicians should contact Dr. Adrian
Danek, Cognitive Neuroscience Section, NINDS, NIH, Building 10, Room 5C205, 10 Center
Drive MSC 1440, Bethesda, MD 20892-1440; telephone: 301-402-6395; e-mail: daneka@ninds.nih.gov.
<top>
Patients with Progressive Supranuclear Palsy
Sought
Scientists at the National Institute of Neurological
Disorders and Stroke (NINDS) studying neurobehavior are seeking patients with progressive
supranuclear palsy for cognitive neuroscience studies.
Eligible patients should be mild to moderately affected,
between the ages of 18 and 70, and have no other current significant disease. Those
enrolled in the study will undergo neuropsychological testing and brain imaging studies.
The studies will be conducted at the National Institutes of Health (NIH) Clinical Center
in Bethesda, MD. All study-related expenses will be paid by the NIH.
For more information, physicians should contact Dr. Jordan
Grafman, Chief, Cognitive Neuroscience Section, NINDS, Building 10, Room 5C205, 10 Center
Drive MSC 1440; Bethesda, MD 20892-1440; telephone: (301) 496-0220; fax: (301) 480-2909;
email: grafmanj@ninds.nih.gov.
<top>
Patients with Seizures Sought for
Studies
Scientists at the National Institute of Neurological
Disorders and Stroke (NINDS) are seeking patients age 5 and older with uncontrolled
partial and secondary generalized seizures for participation in studies of experimental
antiepileptic drugs and transcranial magnetic stimulation. NINDS scientists are also
seeking patients with seizures for studies of brain mapping with PET and MRI scans.
Younger children with new onset seizures may be eligible for some studies.
Patients will be screened to determine eligibility. The
studies will take place at the National Institutes of Health (NIH) Clinical Center in
Bethesda, MD. All study-related expenses will be paid by the NIH.
For more information, physicians should contact Dr.
William Theodore, Chief, Clinical Epilepsy Section, NINDS, NIH, Building 10, Room 5C205,
10 Center Drive MSC 1408, Bethesda, MD 20892-1408; telephone: (301) 496-1505.
<top>
NINDS Seeks Patients with Stroke for
Study of Motor Function Recovery
Scientists at the National Institute of Neurological
Disorders and Stroke (NINDS) are seeking stroke patients for participation in studies to
test two interventions geared to improve recovery of motor function and to identify the
brain areas associated with motor recovery if it occurs.
Participants must be older than 18 years of age and have
had a stroke at least 6 months ago that affected movements on the right side of the body.
The studies will include inpatient rehabilitation therapy, electroencephalography (EEG),
magnetic stimulation, and cognitive and neuroimaging testing. The studies will take place
at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD. All
study-related expenses will be paid by the NIH.
For more information, physicians should send a referral
letter, a copy of the patient's hospital medical records, and a copy of the patient's last
brain MRI or CT scan to: Elaine Considine, Patient Care Coordinator, or Dr. George
Wittenberg, Human Cortical Physiology Section, NINDS, NIH, Building 10, Room 5N234, 10
Center Drive MSC 1430, Bethesda, MD 20892-1430; telephone: (301) 496-0600; fax: (301)
402-1007.
<top>
Patients with Syringomyelia Sought
for Study of Physiology
Investigators at the National Institute of Neurological
Disorders and Stroke (NINDS) are seeking patients with syringomyelia for studies of the
pathophysiology of the disorder. Patients will undergo testing both before and after
receiving surgical treatment for this condition.
To be eligible, patients must be 18 to 70 years old and
must have syringomyelia associated with a pathologic process at the craniocervical
junction, such as Arnold-Chiari malformation. Prior surgery does not exclude patients from
the trial, but patients who are pregnant or are suffering from bleeding disorders will not
be accepted. This study will take place at the National Institutes of Health (NIH)
Clinical Center, Bethesda, MD. All treatment-related expenses will be paid by the NIH.
For more information, physicians should contact Dr. Edward
H. Oldfield, Chief, Surgical Neurology Branch, NINDS, NIH, Building 10, Room 5D37, 10
Center Drive MSC 1414, Bethesda, MD 20892-1414; telephone: (301) 496-5728.
<top>
Patients with Upper or Lower
Extremity Amputations Sought for Study
Investigators at the National Institute of Neurological
Disorders and Stroke (NINDS) are seeking patients with upper or lower extremity
amputations to participate in studies of reorganization of motor and sensory functions.
Patients with and without phantom sensations or phantom
pain are eligible. The studies are noninvasive and may include magnetic resonance imaging
(MRI), magnetic stimulation, electroencephalography (EEG), and evaluations using scales of
pain and phantom sensations. The studies will take place at the National Institutes of
Health (NIH) Clinical Center in Bethesda, MD. All study-related expenses will be paid by
the NIH.
For more information, physicians should contact Elaine
Considine, Human Cortical Physiology Section, NINDS, NIH, Building 10, Room 5N234, 10
Center Drive MSC 1430, Bethesda, MD 20892-1430; telephone: (301) 496-0600; fax: (301)
402-1007.
